Desentum
Latest round
- Series A
Last raised
- Jan 2017
Total raised
- $2M
Investors
- 4
About Desentum
Based in Espoo, Finland, and founded in 2011, Desentum OY is a research-oriented, clinical-stage biopharmaceutical company specialized in developing novel types of allergen immunotherapy products. The company was spun-off from VTT technical Research Centre of Finland, following scientific discoveries made by research groups at the University of Eastern Finland and VTT about the mechanism triggering allergic reactions. Founder Pekka Mattila will remain as CEO of the company. Desentum offers subcutaneous allergen immunotherapies and allergy vaccines to provide long-term relief from allergic symptoms. Desentum’s product development targets both aeroallergens and food allergens. Desentum has completed a First-in-Human clinical study with the lead product candidate, birch pollen hypoallergen DM-101 which is in the company's pipeline. The company is still conducting further clinical development of DM-101. The company generates revenue by conducting R&D as well as development and manufacture of new modified hypoallergens and allergen immunotherapies that help with allergy symptoms.
Who invested in Desentum
4 investors across 2 rounds
See all investors in Desentum
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Desentum
Who invested in Desentum?
Desentum has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Desentum raised?
Desentum has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Desentum last raise money?
Desentum's most recent round on record is a Series A, in Jan 2017.
What does Desentum do?
Based in Espoo, Finland, and founded in 2011, Desentum OY is a research-oriented, clinical-stage biopharmaceutical company specialized in developing novel types of allergen immunotherapy products.
Where is Desentum headquartered?
Desentum is headquartered in Espoo, Finland.
Which VCs invest in companies like Desentum?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at Desentum's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Desentum? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.